Ocugen Signs License Agreement for OCU400 in Korea

Ocugen ( (OCGN) ) has provided an update.

On June 5, 2025, Ocugen, Inc. held its 2025 Annual Meeting of Stockholders virtually, where key proposals were voted on, including the election of directors and the ratification of an independent public accountant. Additionally, Ocugen announced the signing of a binding term sheet for the license of its OCU400 modifier gene therapy for retinitis pigmentosa in Korea, which includes upfront fees, development milestones, and sales royalties. This agreement aligns with Ocugen’s strategy to partner with established companies to expand its reach in treating retinitis pigmentosa patients and is expected to enhance its market presence in Korea.

The most recent analyst rating on (OCGN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page.

Spark’s Take on OCGN Stock

According to Spark, TipRanks’ AI Analyst, OCGN is a Neutral.

Ocugen’s overall stock score reflects significant financial challenges offset by strong technical indicators and promising developments in its gene therapy pipeline. The financial instability and valuation concerns weigh heavily on the score, but optimism from the earnings call and technical momentum provide some balance.

To see Spark’s full report on OCGN stock, click here.

More about Ocugen

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies to address major blindness diseases. The company aims to make an impact on patients’ lives through innovative scientific approaches and has developed a breakthrough modifier gene therapy platform to address significant unmet medical needs for large patient populations.

Average Trading Volume: 4,120,255

Technical Sentiment Signal: Sell

Current Market Cap: $248.7M

Learn more about OCGN stock on TipRanks’ Stock Analysis page.